Biblio
“Blood Pressure and Later-Life Cognition in Hispanic and White Adults (BP-COG): A Pooled Cohort Analysis of ARIC, CARDIA, CHS, FOS, MESA, and NOMAS.”, J Alzheimers Dis, vol. 89, no. 3, pp. 1103-1117, 2022.
, “Brain Tissue-Derived Extracellular Vesicles in Alzheimer's Disease Display Altered Key Protein Levels Including Cell Type-Specific Markers.”, J Alzheimers Dis, vol. 90, no. 3, pp. 1057-1072, 2022.
, “Can Diet Supplements of Macular Pigment of Lutein, Zeaxanthin, and Meso-zeaxanthin Affect Cognition?”, J Alzheimers Dis, vol. 87, no. 3, pp. 1079-1087, 2022.
, “Cancer and Vascular Comorbidity Effects on Dementia Risk and Neuropathology in the Oldest-Old.”, J Alzheimers Dis, vol. 90, no. 1, pp. 405-417, 2022.
, “Cerebrospinal Fluid Sphingomyelins in Alzheimer's Disease, Neurodegeneration, and Neuroinflammation.”, J Alzheimers Dis, vol. 90, no. 2, pp. 667-680, 2022.
, “Characterization of Mild Cognitive Impairment and Dementia among Community-Dwelling Mexican Americans and Non-Hispanic Whites.”, J Alzheimers Dis, vol. 90, no. 2, pp. 905-915, 2022.
, “Circulating Cell-Free Genomic DNA Is Associated with an Increased Risk of Dementia and with Change in Cognitive and Physical Function.”, J Alzheimers Dis, vol. 89, no. 4, pp. 1233-1240, 2022.
, “Clinical Utility of Cerebrospinal Fluid Aβ42 and Tau Measures in Diagnosing Mild Cognitive Impairment in Early Onset Dementia.”, J Alzheimers Dis, vol. 87, no. 2, pp. 771-780, 2022.
, “Combinational Drug Repurposing from Genetic Networks Applied to Alzheimer's Disease.”, J Alzheimers Dis, vol. 88, no. 4, pp. 1585-1603, 2022.
, “Comparative Analysis of Alzheimer's Disease Cerebrospinal Fluid Biomarkers Measurement by Multiplex SOMAscan Platform and Immunoassay-Based Approach.”, J Alzheimers Dis, vol. 89, no. 1, pp. 193-207, 2022.
, “DNA Damage Increases Secreted Aβ40 and Aβ42 in Neuronal Progenitor Cells: Relevance to Alzheimer's Disease.”, J Alzheimers Dis, vol. 88, no. 1, pp. 177-190, 2022.
, “Does Loss of Integrity of the Cingulum Bundle Link Amyloid-β Accumulation and Neurodegeneration in Alzheimer's Disease?”, J Alzheimers Dis, vol. 89, no. 1, pp. 39-49, 2022.
, “The Effectiveness of GRADIOR: A Neuropsychological Rehabilitation Program for People with Mild Cognitive Impairment and Mild Dementia. Results of a Randomized Controlled Trial After 4 and 12 Months of Treatment.”, J Alzheimers Dis, vol. 86, no. 2, pp. 711-727, 2022.
, “Effects of a 6-Month Multifaceted Diet and Exercise Intervention on Cognition in Older Adults at Risk of Cognitive Decline: The PONDER Double-Blind, Placebo-Controlled Randomized Trial.”, J Alzheimers Dis, vol. 89, no. 1, pp. 247-263, 2022.
, “Evoked Cortical Depolarizations Before and After the Amyloid Plaque Accumulation: Voltage Imaging Study.”, J Alzheimers Dis, vol. 88, no. 4, pp. 1443-1458, 2022.
, “Excretion of Amyloid-β in the Gastrointestinal Tract and Regulation by the Gut Microbiota.”, J Alzheimers Dis, vol. 90, no. 3, pp. 1153-1162, 2022.
, “Expression Changes in Mitochondrial Genes Affecting Mitochondrial Morphology, Transmembrane Potential, Fragmentation, Amyloidosis, and Neuronal Cell Death Found in Brains of Alzheimer's Disease Patients.”, J Alzheimers Dis, vol. 90, no. 1, pp. 119-137, 2022.
, “Frontal Atrophy and Executive Dysfunction Relate to Complex Numbers Impairment in Progressive Supranuclear Palsy.”, J Alzheimers Dis, vol. 88, no. 4, pp. 1553-1566, 2022.
, “Glucometabolic Changes Are Associated with Structural Gray Matter Alterations in Prodromal Dementia.”, J Alzheimers Dis, vol. 89, no. 4, pp. 1293-1302, 2022.
, “High Soluble Amyloid-β42 Predicts Normal Cognition in Amyloid-Positive Individuals with Alzheimer's Disease-Causing Mutations.”, J Alzheimers Dis, vol. 90, no. 1, pp. 333-348, 2022.
, “HMGCS2-Induced Autophagic Degradation of Tau Involves Ketone Body and ANKRD24.”, J Alzheimers Dis, vol. 91, no. 1, pp. 407-426, 2022.
, “Impaired Experience-Dependent Refinement of Place Cells in a Rat Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 86, no. 4, pp. 1907-1916, 2022.
, “Importance of Accounting for Regional Differences in Modifiable Risk Factors for Alzheimer's Disease and Related Dementias: The Case for Tailored Interventions.”, J Alzheimers Dis, vol. 89, no. 2, pp. 563-570, 2022.
, “Improved Alzheimer's Disease versus Frontotemporal Lobar Degeneration Differential Diagnosis Combining EEG and Neurochemical Biomarkers: A Pilot Study.”, J Alzheimers Dis, vol. 90, no. 4, pp. 1739-1747, 2022.
, ,